Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22580318 | 0.92 | HRH4 (0.38) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15183474 | 0.82 | HRH4 (0.36) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL21015515 | 0.78 | — | — | |
| SCHEMBL15183492 | 0.76 | HRH4 (0.39) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL9624660 | 0.75 | HRH4 (0.47) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2478778 | 0.75 | HRH4 (0.42) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23696097 | 0.75 | MEN1 (0.34) | HRH4HRH3PKM | |
| SCHEMBL16326390 | 0.75 | L3MBTL1 (0.37) | — | |
| SCHEMBL21015399 | 0.74 | HRH4 (0.40) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL21015249 | 0.74 | HRH4 (0.40) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HRH4 3886/4885HRH3 3631/4885ALDH1A1 2776/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH4 3886/4885HRH3 3631/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.